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Package insertsAbstract Objective: To determine the effect of providing different formats about side effect infor-
mation (verbal versus numerical) to acne patients in Saudi Arabia that are newly prescribed Roac-
cutane.
Design: A prospective study assessing patients’ degree of estimation about side effect informa-
tion.
Participants: One hundred and forty-one acne patients newly prescribed Roaccutane.
Settings: Four dermatology clinics in Riyadh. Two in tertiary hospitals and the other two in pri-
vate clinics.
Intervention: Each patient received information about two different side effects for Roaccutane.
The side effect provided was supplemented with the probability of occurrence, which was written
either in words or in numbers. (Dry eye ‘‘very common’’ or ‘‘30%’’; Loss of hair ‘‘rare’’ or ‘‘0.01%’’).
Main outcome measures: Patient’s estimation of side effect occurrence. Other outcomes were the
likelihood of experiencing the side effect, the severity of the side effect, their perception of risk of
the side effects to their general health, their satisfaction with the information provided and, whether
the information provided will inﬂuence their decision to take the medicine.
Result: The mean estimate for side effect occurrence for the dry eyes was 46% in the verbal group
and 41% in the numerical group (p= 0.5); for loss of hair it was 50% in the verbal group and 39% in
the numerical group (p= 0.03). There are no signiﬁcant differences between verbal and numerical
groups regarding the remaining measures.
Conclusion: Patients overestimate the probability of occurrence of side effect. Verbal format of
probability of occurrence is associated with higher estimation than the numerical format.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
An active role of patients in the decision-making process with
regard to their treatment is becoming increasingly important,
and discussing the risks and beneﬁts of treatment options is
34 L. Al Juffali et al.therefore an essential part of modern health care
(Timmermansa et al., 2004). Recent studies have shown that
the most information required by patients is information about
side effects (Dickinson and Raynor, 2003).
The information on side effects currently provided to pa-
tients in Saudi Arabia other than oral communication is lim-
ited to package insert leaﬂets, which mostly use words
(Al –Aqeel, 2012). The European Union (EU) in 1999 devel-
oped guidelines on the readability of leaﬂets which indicate
that the frequency of side effects could be denoted by the use
of ﬁve verbal descriptions (very common, common, uncom-
mon, rare and, very rare) each word is correlated to a numer-
ical value (Knapp et al., 2004). After these guidelines were
introduced a series of empirical studies were begun to try to
ﬁnd out patients’ interpretation of side effect probability when
presented in either the verbal descriptors or in their numerical
equivalents. Berry et al. started these studies using hypothetical
scenarios presented to people about being at the doctor and
prescribed a medicine each scenario was assigned with its side
effect probability either in words or number. The ﬁrst study
was on 268 students, they estimated the probability of a side
effect occurrence that is common (1–10%) to be 45% (Berry,
2004). Berry (2004) conducted two other studies on the general
population. Two hundred and thirty-two participants were gi-
ven information regarding a side effect that is very common
(15%) the participants were stratiﬁed based on their ages into
groups (18–40, 41–60 and 60+). Patients provided with the
verbal descriptor very common had overestimated the fre-
quency to 65% in all the different age groups (Berry, 2004).
The ﬁnal study was on 360 of the general population, pre-
sented with either a rare side effect or a common one in either
words or numerical format and again patients with the word
format had overestimated the side effect (Berry and Knapp,
2002). Tan et al. (2005) in Singapore used a hypothetical sce-
nario given to 95 healthcare professionals and students about
the risk of side effects of an inﬂuenza vaccine. The information
was presented in either a probability format (5%) or a fre-
quency format (1 out of 20). Respondents presented with a
‘‘5% risk’’ were more likely to describe the risk as ‘‘uncom-
mon’’ or ‘‘rare’’, as compared to respondents presented with
a risk of ‘‘one out of twenty’’ (Tan et al., 2005). The previous
four studies done by Berry et al. as mentioned earlier were
based on hypothetical scenarios that limited their applicability
to real patients who actually read the leaﬂet. This led Berry
et al. to study their hypothesis on 120 patients taking statins
in different settings a cardiac rehabilitation clinic, a commu-
nity pharmacy and a GP asthma clinic. The patients’ in thisTable 1 Information provided to patients.
Side eﬀect Verbal descriptor
Dry eye 1 Group
Roaccutane is associated with some side eﬀect
It can cause dry eyes. This side eﬀect is a very
common side eﬀect.
Loss of Hair 2 Group
Roaccutane is associated with some side eﬀect
It can cause loss of hair. It is a rare side eﬀecstudy have been provided with information about a common
side effect constipation that occurs in 2.5%. Patients in the ver-
bal group had overestimated the occurrence as 34% while pa-
tients given the numerical format stated the occurrence as 8%
(Knapp et al., 2004).
Studies in the area of risk perception in Saudi Arabia are
very limited. There is a need to ﬁnd out how Saudi Arabians
understand and perceive different format of information and
its effect on their decision-making. This study was conducted
to compare the effect of providing verbal format versus numer-
ical format when communicating written information about
side effect probability to acne patients newly prescribed Roac-
cutane in Saudi Arabia.
2. Methods
2.1. Setting
Patients who were newly prescribed Roaccutane for the ﬁrst
time were recruited from the dermatological clinics of a ter-
tiary teaching hospital (A), a Military tertiary hospital (B),
private sector hospital specialized in dermatology (C), and
a private sector clinic specialized in dermatology (D).
The study was carried out from June 2005 to November
2005.
2.2. Source of data
A self-completed questionnaire to be completed anonymously
was distributed by the nurse in the clinic to any patient newly
prescribed Roaccutane .The questionnaire is based on the one
developed by Knapp et al. (2004) the questionnaire was trans-
lated into Arabic.
It is a two page questionnaire the ﬁrst page contained the
purpose of the study, instructions on how to answer the ques-
tions, and a statement containing information about one side
effect and the frequency of its occurrence either in words or
numbers. The statement was provided to the patients in four
different formats. Each patient participating in the study took
just one format (Table 1).
The verbal descriptors and their numerical equivalents used
in this study were based on those proposed ones by the EC
very common (>10%) and very rare (<0.01%) (European
Commission, 1998). The incidence rates of the side effect were
taken from the European Medicines Agency EMEA which
were calculated from pooled clinical trial data involving 824Numerical equivalent
3 Group
s. Roaccutane is associated with some side eﬀects. It
can cause dry eyes. This side eﬀect occurs in 30%
(30 in 100) of patients who take the medicine.
Group 4
s.
t.
Roaccutane is associated with some side eﬀects. It
can cause loss of hair. This side eﬀect occurs in
0.01% (1 in 10000) of patients who took this
medicine.
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Agency, 2003).
After reading the information provided, participants were
asked to give a percentage probability of the likelihood of hav-
ing the side effect. They were also asked to respond to ﬁve
questions; about the overall likelihood of their experiencing
the side effect, the severity of the side effect, their perception
of risk of the side effects to their general health, their satisfac-
tion with the information provided and, whether the informa-
tion provided will inﬂuence their decision to take the medicine.
Responses to these questions were recorded on a Likert scale
(1–6). Finally, patients were asked about their age, sex and
educational level.
The questionnaire was organized in alternating order in a
pack. The nurse of the clinic was instructed to give the next
questionnaire from the pack to any patient newly prescribed
Roaccutane. The nurse who distributed the questionnaire
was not aware of which of the four different formats was
administered to each patient.
Two dermatologists have been given the Arabic version of
the questionnaire to ensure the content validity. Face validity
has been assessed by three laymen their ages are within the
age of the sample. A pilot study has been completed with 10
patients and reliability has been tested by re-giving the ques-
tionnaire again after 1 month, which is the follow up duration
in a patient newly prescribed Roaccutane. The results were
correlated using Spearman’s correlation test.
2.3. Analysis of data
The main outcome measure was the estimate of the likelihood
of the side effect occurring. Secondary measures were related
to the Likert scale responses to the ﬁve additional questions.
The main outcome measure was analyzed using independent
t tests after ensuring approximately normal distributions.
The Likert scale responses were analyzed using the Chi square
test. The statistical analysis was performed using SPSS version
13.0.Table 2 Demographic characteristics of the patients within the gro
Demographic characteristics Dry eye (%)
Words (n = 34) N
Age Less than 15 3
16–20 24.2 31
21–25 54.5 40
26–30 18.2 22
More than 30 2.
Gender Male 23.5 25
Female 76.5 71
Education None
Intermediate 9.1 5.
High school 27.3 34
College 60.6 57
Post graduate degree 3 2.
Hospital A 5.9
B 32.4 22
C 47.1 54
D 14.7 223. Results
One hundred and forty-one patients were recruited (96 wo-
men) of mean age 23 years (range 21–25). Sixty percent of par-
ticipants had a college qualiﬁcation degree (Table 2). The
majority of participants were recruited from the two private
clinics (78%, n= 141). The patients recruited to each of the
four groups were comparable with respect to demographic
data. In general, patients had overestimated the probability
of occurrence in the four groups.
3.1. Dry eyes (‘‘very common’’ versus 30%)
The mean estimate of the percentage of people who would
experience dry eyes was 46% (SD31.9) in the verbal group
and 41% (SD27.7) in the numerical group (t= 0.291;
p= 0.5; 95%CI -11.07–19.81).
Patients in the verbal group thought that they were more
likely to have the side effect then the numerical group but this
difference was not statistically signiﬁcant (p= 0.1).
There were no signiﬁcant differences in the patients’ rating
of their satisfaction with information provided, severity of side
effect, risk to health and the effect of information on decision
to take the medicine (Table 3).
Eighty-ﬁve percent of patients in the verbal group who indi-
cated that the side effect was not severe considered this infor-
mation would not affect their decision to take the medicine.
While 33% who rated the side effect very severe indicated that
this information will affect the decision to take the medicine
(p= 0.013). In the numerical group, all patients who rated
that the side effect is not severe considered the information
would not affect their decision to take the medicine (p= 0.02).
3.2. Loss of hair (‘‘rare’’ versus 0.01%)
The mean estimate of the likelihood of having loss of hair was
50% (SD 26.3, median = 50%) in the verbal group and 39%.ups.
Loss of hair (%)
umbers (n = 35) Words (n = 40) Numbers (n = 32)
2. 5
.4 30 37.5
40 34.4
.9 22.5 28.1
9 5
.7 46.2 22.6
.4 53.8 77.4
5.1
7 7.7
.3 20.5 29
.1 59 71
9 7.7
3.1
.9 22.5 25
.3 60 46.9
.9 17.5 25
Table 3 Percentage of participants’ responses to the Likert scale variables.
Dry eye x2 test P value Loss of hair x2 test P value
Words (n = 34) Numbers (n = 35) Words (n = 40) Numbers (n = 32)
Satisfaction with information
Not at all satisﬁed 4.52 0.2 2.5 3.1 6.99 0.03
Unsatisﬁed 8.8 7.5 3.1
Slightly unsatisﬁed 18.2 26.5 17.5 6.3
Slightly satisﬁed 18.2 17.6 20 12.5
Satisﬁed 33.3 20.6 25 18.8
Very satisﬁed 30.3 26.5 27.5 56.3
Severity of side eﬀects
Not at all severe 11.8 5.7 3.93 0.5 7.5 18.8 3.38 0.4
Not severe 11.8 8.6 22.5 12.5
Slightly not severe 23.5 37.1 25 28.1
Slightly severe 26.5 28.6 22.5 25
Severe 14.7 17.1 15 9.4
Very severe 11.8 2.9 7.5 6.3
Likelihood of occurrence
Not at all likely 3 14.3 7.87 0.1 10 3.1 4.98 0.4
Not likely 15.2 25.7 15 31.1
Slightly unlikely 15.2 17.1 22.5 28.1
Slightly likely 18.2 20 22.5 12.5
Likely 18.2 14.3 15 15.6
Very likely 30.3 8.6 15 9.4
Risk to health
No risk at all 12.1 11.4 6.17 0.1 22.5 18.8 4.9 0.4
Not risky 18.2 286 12.5 31.3
Slightly not risky 42.4 34.3 32.5 21.9
Slightly risky 21.2 17.1 15 18.8
Risky 8.6 10 6.3
Very risky 6.1 7.5 3.1
Eﬀect on decision making
Deﬁnitely will not 27.3 23.5 1.93 0.8 40 31.3 6.47 0.5
Will not 18.2 23.5 12.5 28.1
Slightly will not 21.2 14.7 20 9.4
Slightly will 21.2 23.5 15 25
Will 3 8.8 5
Deﬁnitely will 9.1 5.9 7.5 6.3
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p= 0.03; 95% CI 0.95–17.94).
Patients in the numerical group were more satisﬁed with the
information provided (p= 0.03). The two groups showed no
statistically signiﬁcant differences on the remaining measures:
severity of side effect, likelihood of occurrence, risk to health
and the effect of information on decision to take the medicine
(Table 3). Eighty-three percent of patients in the verbal group
who rated the side effect not severe indicated that the informa-
tion provided did not affect their decision to take the medicine.
On the other hand patients who rated the side effect severe con-
sidered the information will affect the decision to take the med-
icine (p= 0.03). Ninety percent of the patients in the numerical
group who rated the side effect not severe indicated that their
information will not affect their decision to take the medicine
(p= 0.03).
4. Discussion
This study conﬁrmsmany other studies that have found that pa-
tients overestimate side effect occurrence when provided infor-
mation in verbal format than in numerical format (Knappet al., 2004; Berry, 2004; Berry and Knapp, 2002; Tan et al.,
2005).
In fact, all types of formats presented to patients in this
study were associated with overestimating the probability of
side effect occurrence. However, the degree of overestimation
differed between the two formats. When verbal format was
presented to patients it was associated with a higher estimation
than the numerical group.
For instance; patients in the ‘‘very rare’’ group stated that
they have 50% probability of experiencing the side effect,
which is 5000 times more than what happens in fact in reality.
In the numerical format group, patients estimated the occur-
rence as 39% that is lower but yet there is an overestimation.
This ﬁnding raises an important issue about the way pa-
tients interpret the information about risks. One of the impor-
tant factors that affect the interpretation is the mode of
presenting risks. Verbal labels of likelihood are viewed as easy
to use; their interpretation is highly variable and dependent on
the speciﬁc context (Burkell, 2004 April). While numbers give
precise information there are a wide number of patients who
do not interpret them correctly. This can be reduced by
presenting numbers as frequencies assigned with the correct
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the numbers (Edwards et al., 2002; Palling, 2003).
Patients were satisﬁed with the information provided never-
theless, the mode of presenting the side effect risk information
did not have any effect on their satisfaction nor did it have any
effect on their decision to take the medicine. Patients in the
‘‘very common’’ group thought they would likely experience
the side effect more than patients in the numerical group.
The patients’ rating of severity and risk to health did not
show any trend or signiﬁcance with respect to the modes of
presentation.
The decision to take the medicine was affected by the per-
ceived severity of the side effect; those who rated the side effect
was very severe had a tendency to change their decision regard-
ing taking the medicine. The health belief model supports this
ﬁnding; that perceived threat motivates people to take action
(Berry, 2004).
These results are in line with Knapp et al. (2004) in terms of
overestimating probabilities when providing information in
the verbal format. The other ﬁndings like patient satisfaction
with information, the severity of the side effects and its effect
on deciding whether or not to take the medication did not
show the same results. An explanation for this ﬁnding could
be that patients in our study are recruited from acne clinics
rather than cardiac clinics which patients in the later are asso-
ciated with more complicated health conditions therefore they
have more experience with risks of medicine and also know
more information about their medicine. Moreover, cardiac pa-
tients are taking their medicine for an average of 15.5 months
that led them to base their estimation based on their experience
with the medicine the whole past months rather than their per-
ception. So when asking a patient about the likelihood of expe-
riencing a side effect from a medicine he has been taking for
more than one year he will underestimate its occurrence
(Knapp, 2004). Thus they are subjected to optimistic bias. In
this study we aimed to include just new patients to overcome
any kind of biases that may be encountered when administer-
ing the medicine for a period of time. Also our patients are dif-
ferent than the Knapp et al. patients, they are younger and
more educated. Another difference is the majority were fe-
males (68%; n= 141) in contrast to Knapp et al. where the fe-
males were less (37%; n= 120) recent studies suggest that
females perceive risks much higher than males (Walker et al.,
2003). The difference in the medicine between the Knapp
et al. and this study is worth mentioning. Roaccutane the med-
icine studied in this study is perceived by many patients as a
cosmetic owing to that acne is a cosmetic problem while in
their study statins are the medicine being studied comparing
the two medicines in terms of patients’ controllability as no pa-
tient come and ask for a statin. A very important difference is
the culture which differs in all aspects and the type of relation-
ship between the patients and their care giver in Saudi Arabia
versus UK in terms of decision making and their expectations
from the decision making process might be different.
The sample of this study is representative of the Saudi pop-
ulation giving that the majority of the Saudi population are
young (Central Department of statistics and information,
2000).
Limitations of this study, ﬁrstly Roaccutane has a very high
efﬁcacy and also a wider side effect proﬁle. Patients with mod-
erate to severe acne are the main candidates for this medicinethey usually come to the clinic asking for this medicine and ac-
cept the risk associated with it.
Secondly, the patients have other sources of information
that may affect their perception of risk. Roaccutane has a risk
management program, that each physician counsels his pa-
tients about the risks and beneﬁt of this medicine.
Another limitation, the numerical probability of occurrence
provided to the loss of hair group 0.01% is very hard to esti-
mate since when asking patients to state a percentage they will
think of a number in between 1% and 100% without consider-
ing fractions as seen in our study.
In conclusion, this study has shown the impact of different
formats of information about the probability of occurrence of
side effects on patients’ perception of risk.
There is an overall overestimating of the probability of side
effect occurrences, however patients presented with the verbal
format had a higher degree of overestimation than patients
presented with the numerical format. This suggests using
numerical equivalents of the side effect probability when com-
municating written information to patients.
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